Just when drug-eluting stents (DES) were going to revolutionize interventional cardiology, new reports that DES may be associated with increased risk of late-stent thrombosis have many physicians...

iffering approaches for the treatment of coronary bifurcation and ostial lesions (CBOL) continue to feed the debate over which stent designs and stenting techniques are most effective.

When it comes to treating patients suffering from heart failure, which is typically defined as a heart whose pumping power is weaker than normal, physicians are facing a paradox.

Author’s Note: For this inaugural article I begin with an insider’s look on the “health” of drug-eluting stents and what lies ahead for this much-debated device.